Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
CLASh | TSXV | CAD | Delayed | |
CLAZF | OTC Markets | USD | Delayed | |
CLASh | CBOE Canada | CAD | Real-time |
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Stuart L. Silverman | 75 | 2015 | Co-Chair of Scientific Advisory Board and Vice President of Medical Affairs |
Robert Farrell | - | 2016 | Chairman, CEO & President |
Li Zhang | - | 2018 | Member of Strategic & Scientific Advisory Board |
Perenlei Enkhbaatar | - | 2021 | Independent Director |
Yong-Hui Jiang | - | - | Member of Scientific Advisory Board |
Deborah Kado | - | - | Member of Scientific Advisory Board |
Robert S. Langer | 74 | 2016 | Member of Scientific Advisory Board |
Salvatore Cuzzocrea | - | 2021 | Independent Director |
Yossi Tam | - | - | Member of Scientific Advisory Board |
Hanns Ulrich Zeilhofer | - | 2018 | Member of Strategic & Scientific Advisory Board |
Garry J. Southan | - | 2021 | Member of Scientific Advisory Board |
Joseph Lynch | - | 2018 | Member of Strategic & Scientific Advisory Board |
Yanekl Gabet | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review